PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
BMRN vs. RCKT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between BMRN and RCKT is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.4

Performance

BMRN vs. RCKT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BioMarin Pharmaceutical Inc. (BMRN) and Rocket Pharmaceuticals, Inc. (RCKT). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%20.00%AugustSeptemberOctoberNovemberDecember2025
-26.50%
-55.69%
BMRN
RCKT

Key characteristics

Sharpe Ratio

BMRN:

-1.10

RCKT:

-1.24

Sortino Ratio

BMRN:

-1.39

RCKT:

-2.28

Omega Ratio

BMRN:

0.78

RCKT:

0.75

Calmar Ratio

BMRN:

-0.58

RCKT:

-0.75

Martin Ratio

BMRN:

-1.86

RCKT:

-1.78

Ulcer Index

BMRN:

18.49%

RCKT:

36.06%

Daily Std Dev

BMRN:

31.36%

RCKT:

51.84%

Max Drawdown

BMRN:

-90.58%

RCKT:

-94.90%

Current Drawdown

BMRN:

-58.93%

RCKT:

-85.54%

Fundamentals

Market Cap

BMRN:

$11.74B

RCKT:

$1.16B

EPS

BMRN:

$1.66

RCKT:

-$2.73

Total Revenue (TTM)

BMRN:

$2.10B

RCKT:

$0.00

Gross Profit (TTM)

BMRN:

$1.63B

RCKT:

-$4.59M

EBITDA (TTM)

BMRN:

$455.03M

RCKT:

-$190.02M

Returns By Period

In the year-to-date period, BMRN achieves a -6.82% return, which is significantly higher than RCKT's -18.77% return.


BMRN

YTD

-6.82%

1M

-8.84%

6M

-26.51%

1Y

-34.44%

5Y*

-7.07%

10Y*

-4.74%

RCKT

YTD

-18.77%

1M

-14.35%

6M

-55.69%

1Y

-62.59%

5Y*

-13.27%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

BMRN vs. RCKT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BMRN
The Risk-Adjusted Performance Rank of BMRN is 66
Overall Rank
The Sharpe Ratio Rank of BMRN is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of BMRN is 66
Sortino Ratio Rank
The Omega Ratio Rank of BMRN is 44
Omega Ratio Rank
The Calmar Ratio Rank of BMRN is 1313
Calmar Ratio Rank
The Martin Ratio Rank of BMRN is 11
Martin Ratio Rank

RCKT
The Risk-Adjusted Performance Rank of RCKT is 33
Overall Rank
The Sharpe Ratio Rank of RCKT is 11
Sharpe Ratio Rank
The Sortino Ratio Rank of RCKT is 11
Sortino Ratio Rank
The Omega Ratio Rank of RCKT is 33
Omega Ratio Rank
The Calmar Ratio Rank of RCKT is 66
Calmar Ratio Rank
The Martin Ratio Rank of RCKT is 22
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

BMRN vs. RCKT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for BioMarin Pharmaceutical Inc. (BMRN) and Rocket Pharmaceuticals, Inc. (RCKT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for BMRN, currently valued at -1.10, compared to the broader market-2.000.002.004.00-1.10-1.24
The chart of Sortino ratio for BMRN, currently valued at -1.39, compared to the broader market-4.00-2.000.002.004.00-1.39-2.28
The chart of Omega ratio for BMRN, currently valued at 0.78, compared to the broader market0.501.001.502.000.780.75
The chart of Calmar ratio for BMRN, currently valued at -0.58, compared to the broader market0.002.004.006.00-0.58-0.75
The chart of Martin ratio for BMRN, currently valued at -1.86, compared to the broader market-10.000.0010.0020.0030.00-1.86-1.78
BMRN
RCKT

The current BMRN Sharpe Ratio is -1.10, which is comparable to the RCKT Sharpe Ratio of -1.24. The chart below compares the historical Sharpe Ratios of BMRN and RCKT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.50AugustSeptemberOctoberNovemberDecember2025
-1.10
-1.24
BMRN
RCKT

Dividends

BMRN vs. RCKT - Dividend Comparison

Neither BMRN nor RCKT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

BMRN vs. RCKT - Drawdown Comparison

The maximum BMRN drawdown since its inception was -90.58%, roughly equal to the maximum RCKT drawdown of -94.90%. Use the drawdown chart below to compare losses from any high point for BMRN and RCKT. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%AugustSeptemberOctoberNovemberDecember2025
-58.93%
-85.54%
BMRN
RCKT

Volatility

BMRN vs. RCKT - Volatility Comparison

The current volatility for BioMarin Pharmaceutical Inc. (BMRN) is 8.51%, while Rocket Pharmaceuticals, Inc. (RCKT) has a volatility of 15.03%. This indicates that BMRN experiences smaller price fluctuations and is considered to be less risky than RCKT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%AugustSeptemberOctoberNovemberDecember2025
8.51%
15.03%
BMRN
RCKT

Financials

BMRN vs. RCKT - Financials Comparison

This section allows you to compare key financial metrics between BioMarin Pharmaceutical Inc. and Rocket Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab